BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Vepafestinib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Vepafestinib\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04683250-2757@assetmemo.bio
DTSTAMP:20261121T010123Z
DTSTART;VALUE=DATE:20300331
DTEND;VALUE=DATE:20300401
SUMMARY:Vepafestinib: Phase 1/2 readout est. (NCT04683250)
DESCRIPTION:Vepafestinib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: 
 Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors
  With RET Gene Abnormalities\nEstimated primary completion: March 2030. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/vepafestinib#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT04683250
URL:https://assetmemo.bio/drug/vepafestinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
